兄弟科技(002562) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥879,221,669.43, representing a 27.54% increase compared to ¥689,370,526.73 in the same period last year[3] - Net profit attributable to shareholders reached ¥103,018,237.25, a significant increase of 826.02% from ¥11,124,807.00 in the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥92,268,971.91, up 836.58% from ¥9,851,726.82 year-on-year[3] - The basic earnings per share rose to ¥0.10, reflecting a 900.00% increase from ¥0.010 in the same quarter last year[3] - Total operating revenue for Q1 2022 was CNY 879,221,669.43, an increase of 27.6% compared to CNY 689,370,526.73 in Q1 2021[21] - Net profit for Q1 2022 reached CNY 103,018,237.25, significantly higher than CNY 11,124,807.00 in Q1 2021, marking an increase of 825.5%[22] - The company reported a comprehensive income total of CNY 167,620,895.50 for Q1 2022, compared to CNY 565,411.01 in Q1 2021[23] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥5,711,681,393.51, a 1.97% increase from ¥5,601,478,127.75 at the end of the previous year[3] - The total assets as of the end of Q1 2022 amounted to CNY 5,711,681,393.51, up from CNY 5,601,478,127.75 at the end of Q1 2021[19] - Total liabilities decreased to CNY 2,519,107,456.40 in Q1 2022 from CNY 2,606,145,107.85 in Q1 2021, a reduction of 3.3%[19] - The total current assets at the end of the reporting period are ¥2,156,437,961.24, compared to ¥2,079,656,949.76 at the beginning of the year, showing an increase of approximately 3.7%[17] Cash Flow - Cash flow from operating activities showed a net outflow of ¥32,496,893.14, an improvement of 56.67% compared to a net outflow of ¥74,991,152.46 in the previous year[3] - The company's cash flow from operating activities for Q1 2022 was CNY 590,209,869.70, compared to CNY 482,428,666.84 in Q1 2021[25] - The net cash flow from operating activities was -32,496,893.14, an improvement from -74,991,152.46 in the previous year[26] - The total cash inflow from operating activities was 649,826,097.25, an increase from 527,984,989.70 year-over-year[26] - The total cash outflow from operating activities was 682,322,990.39, compared to 602,976,142.16 in the previous year[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,539[10] - The largest shareholder, Qian Zhida, holds 24.22% of shares, amounting to 257,395,438 shares, with 193,046,578 shares pledged[10] Research and Development - Research and development expenses increased by 113.30% to ¥33,703,410.70, reflecting the company's commitment to innovation[7] - Research and development expenses for Q1 2022 were CNY 33,703,410.70, an increase of 113.5% from CNY 15,801,279.23 in Q1 2021[22] Government Support and Penalties - The company received government subsidies amounting to ¥5,311,934.17, which contributed positively to its financial performance[6] - The company received an administrative penalty of ¥12,000 due to non-compliance with safety regulations, which has been paid and rectified[12] Investment Plans - The company plans to invest a total of ¥2.5 billion in the construction of an international pharmaceutical industry base, with ¥1.5 billion allocated for fixed assets and ¥1 billion for R&D[14] - The company has adjusted the use of raised funds, reallocating ¥385 million from a natural flavor project to a phenol and phenolic derivatives project[15]